Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy Publisher Pubmed

Summary: Study shows MSC-derived EVs may treat inflammatory diseases like kidney or liver issues. Are EVs the future of therapy? #StemCells #RegenerativeMedicine

Jafarinia M1 ; Alsahebfosoul F1 ; Salehi H2 ; Eskandari N1 ; Ganjalikhanihakemi M1
Authors

Source: Immunological Investigations Published:2020


Abstract

In recent years, mesenchymal stem/stromal cells (MSCs) have widely been considered as therapeutic tools in basic researches and clinical trials. Accumulating evidence supports the idea that MSCs perform their therapeutic roles in paracrine manner especially through trophic factors and extracellular vesicles (EVs). Compared to cells, EVs have several advantages to be used as therapeutic agents, such as they lack self-replicating capabilities, dangers of ectopic differentiation, and tumor formation, genetic instability, and cellular rejection by the immune system. Since the MSC-derived EVs (MSC-EVs) appear to exert similar therapeutic effects of their parent cells, such as ability to arrive themselves to the site of injury and immunomodulatory properties, MSC-EVs have been widely studied in many animal models, including kidney, liver, cardiovascular, immunological, and neurological diseases. Regarding this, MSC-EVs look to be a novel and interesting approach to be studied in clinical trials of different inflammatory diseases. In this review, we summarize the properties and applications of MSC-EVs in different diseases. © 2020 Taylor & Francis Group, LLC.
Other Related Docs
18. Microrna: Relevance to Stroke Diagnosis, Prognosis, and Therapy, Journal of Cellular Physiology (2018)